Brian J. Van Lenten

8.4k citations

57 papers · 6.9k indexed · 4 hit papers · h-index 42

Clinical Biochemistry top 0.1%
- Paraoxonase enzyme and polymorphisms 15
Biochemistry top 0.5%
- Antioxidant Activity and Oxidative Stress 9
Endocrinology, Diabetes and Metabolism top 0.5%
- Diabetes, Cardiovascular Risks, and Lipoproteins 21
Immunology top 2%
- Atherosclerosis and Cardiovascular Diseases 9
Cancer Research top 2%
- Cancer, Lipids, and Metabolism 10
Surgery
- Cholesterol and Lipid Metabolism 12
- Lipoproteins and Cardiovascular Health 11
Molecular Biology
- Peroxisome Proliferator-Activated Receptors 9

Co-authors: Alan M. Fogelman Mohamad Navab Srinivasa T. Reddy Susan Hama Alan C. Wagner Aldons J. Lusis G.M. Anantharamaiah Peter A. Edwards
Cited by: Clinical Biochemistry Biochemistry Endocrinology, Diabetes and Metabolism
Journals: Proceedings of the National Academy of Sciences (2 papers)Journal of Biological Chemistry (3 papers)Circulation (3 papers)
Partner nations: United States Poland Netherlands

In The Last Decade

Brian J. Van Lenten

57 papers receiving 6.7k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2011 Nature Reviews Cardiology
2004 Journal of Lipid Research
1996 Arteriosclerosis Thrombosis and Vascular Biology
1995 Journal of Clinical Investigation

Peers

Countries citing papers authored by Brian J. Van Lenten

Since Specialization

Citations

This map shows the geographic impact of Brian J. Van Lenten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian J. Van Lenten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian J. Van Lenten more than expected).

Fields of papers citing papers by Brian J. Van Lenten

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian J. Van Lenten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian J. Van Lenten. The network helps show where Brian J. Van Lenten may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Brian J. Van Lenten, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Brian J. Van Lenten Line = papers co-authored together Brian J. Van Lenten links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Isolevuglandin-Type Lipid Aldehydes Induce the Inflammatory Response of Macrophages by Modifying Phosphatidylethanolamines and Activating the Receptor for Advanced Glycation Endproducts Antioxidants and Redox Signaling ·Lilu Guo,Zhongyi Chen,Venkataraman Amarnath,Patricia G. Yancey,Brian J. Van Lenten,Justin R. Savage,Sergio Fazio,MacRae F. Linton,Sean S. Davies	2015	23
2	A novel approach to oral apoA-I mimetic therapy Journal of Lipid Research ·A. Chattopadhyay,Mohamad Navab,Greg Hough,Feng Gao,David Meriwether,Víctor Grijalva,James R. Springstead,Mayakonda N. Palgnachari,Ryan Namiri‐Kalantari,Feng Su,Brian J. Van Lenten,Alan C. Wagner,G.M. Anantharamaiah,Robin Farias‐Eisner,Srinivasa T. Reddy,Alan M. Fogelman	2013	73
3	Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid Journal of Lipid Research ·Mohamad Navab,Greg Hough,Georgette M. Buga,Feng Su,Alan C. Wagner,David Meriwether,A. Chattopadhyay,Feng Gao,Víctor Grijalva,Janet Seager Danciger,Brian J. Van Lenten,Elin Org,Aldons J. Lusis,Calvin Pan,G.M. Anantharamaiah,Robin Farias‐Eisner,Susan S. Smyth,Srinivasa T. Reddy,Alan M. Fogelman	2013	58
4	Apolipoprotein A-I mimetic peptides Current Atherosclerosis Reports ·Brian J. Van Lenten,Alan C. Wagner,G.M. Anantharamaiah,Mohamad Navab,Srinivasa T. Reddy,Georgette M. Buga,Alan M. Fogelman	2008	73
5	Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis Clinical Immunology ·Christina Charles‐Schoeman,Mona Lisa Banquerigo,Susan Hama,Mohamad Navab,Grace S. Park,Brian J. Van Lenten,Alan C. Wagner,Alan M. Fogelman,Ernest Brahn	2008	41
6	The role of dysfunctional HDL in atherosclerosis Journal of Lipid Research ·Mohamad Navab,Srinivasa T. Reddy,Brian J. Van Lenten,G.M. Anantharamaiah,Alan M. Fogelman	2008	172
7	Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits Journal of Lipid Research ·Brian J. Van Lenten,Alan C. Wagner,Mohamad Navab,G.M. Anantharamaiah,Susan Hama,Srinivasa T. Reddy,Alan M. Fogelman	2007	91
8	Mechanisms of Disease: proatherogenic HDL—an evolving field Nature Clinical Practice Endocrinology &#38 Metabolism ·Mohamad Navab,G.M. Anantharamaiah,Srinivasa T. Reddy,Brian J. Van Lenten,Benjamin J. Ansell,Alan M. Fogelman	2006	195
9	The double jeopardy of HDL Annals of Medicine ·Mohamad Navab,G. M. Ananthramaiah,Srinivasa T. Reddy,Brian J. Van Lenten,Benjamin J. Ansell,Susan Hama,Greg Hough,Eugene Bachini,Víctor Grijalva,Alan C. Wagner,Zory Shaposhnik,Alan M. Fogelman	2005	116
10	Thematic review series: The Pathogenesis of Atherosclerosis The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDLbreakdown → Journal of Lipid Research ·Mohamad Navab,G. M. Ananthramaiah,Srinivasa T. Reddy,Brian J. Van Lenten,Benjamin J. Ansell,Gregg C. Fonarow,Kambiz Vahabzadeh,Susan Hama,Greg Hough,Naeimeh Kamranpour,Judith A. Berliner,Aldons J. Lusis,Alan M. Fogelman	2004	546
11	Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal Current Opinion in Lipidology ·Mohamad Navab,G.M. Anantharamaiah,Srinivasa T. Reddy,Brian J. Van Lenten,Geeta Datta,David W. Garber,Alan M. Fogelman	2004	67
12	Oxidized lipids as mediators of coronary heart disease Current Opinion in Lipidology ·Mohamad Navab,Susan Hama,Srinu T. Ready,Carey J. Ng,Brian J. Van Lenten,Hillel Laks,Alan M. Fogelman	2002	91
13	Oxidized Phospholipids Induce Changes in Hepatic Paraoxonase and ApoJ but Not Monocyte Chemoattractant Protein-1 via Interleukin-6 Journal of Biological Chemistry ·Brian J. Van Lenten,Alan C. Wagner,Mohamad Navab,Alan M. Fogelman	2001	104
14	Correction Journal of Clinical Investigation ·Mohamad Navab,Susan Hama-Levy,Brian J. Van Lenten,Gregg C. Fonarow,Cheryll J. Cardinez,Lawrence W. Castellani,Marie‐Luise Brennan,Bert N. La Du	1997	2
15	Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. Journal of Clinical Investigation ·Mohamad Navab,Susan Hama-Levy,Brian J. Van Lenten,Gregg C. Fonarow,C J Cardinez,Lawrence W. Castellani,Marie-Luise Brennan,Aldons J. Lusis,Alan M. Fogelman,Bert N. La Du	1997	263
16	Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles. Journal of Clinical Investigation ·Lawrence W. Castellani,Mohamad Navab,Brian J. Van Lenten,Catherine C. Hedrick,Susan Hama,Aimie M. Goto,Alan M. Fogelman,Aldons J. Lusis	1997	153
17	Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures.breakdown → Journal of Clinical Investigation ·Brian J. Van Lenten,Susan Hama,Frederick C. de Beer,Diana M. Stafforini,Thomas M. McIntyre,Stephen M. Prescott,Bert N. La Du,Alan M. Fogelman,M. Navab	1995	678
18	A new antiinflammatory compound, leumedin, inhibits modification of low density lipoprotein and the resulting monocyte transmigration into the subendothelial space of cocultures of human aortic wall cells. Journal of Clinical Investigation ·Mohamad Navab,Susan Hama,Brian J. Van Lenten,Davis C. Drinkwater,Hillel Laks,Alan M. Fogelman	1993	19
19	Interaction of monocytes with cocultures of human aortic wall cells involves interleukins 1 and 6 with marked increases in connexin43 message. Journal of Clinical Investigation ·M. Navab,Feng Liao,G P Hough,L. A. Ross,Brian J. Van Lenten,T B Rajavashisth,A.J. Lusis,Hillel Laks,Davis C. Drinkwater,Alan M. Fogelman	1991	44
20	Low density lipoproteins transfer bacterial lipopolysaccharides across endothelial monolayers in a biologically active form. Journal of Clinical Investigation ·Mohamad Navab,G P Hough,Brian J. Van Lenten,J A Berliner,Alan M. Fogelman	1988	48

About Brian J. Van Lenten

Brian J. Van Lenten is a scholar working on Clinical Biochemistry, Biochemistry and Endocrinology, Diabetes and Metabolism, having authored 57 papers that have together received 6.9k indexed citations. Recurring topics across this work include Diabetes, Cardiovascular Risks, and Lipoproteins (21 papers), Paraoxonase enzyme and polymorphisms (15 papers), Cholesterol and Lipid Metabolism (12 papers), Lipoproteins and Cardiovascular Health (11 papers), Cancer, Lipids, and Metabolism (10 papers), Atherosclerosis and Cardiovascular Diseases (9 papers), Peroxisome Proliferator-Activated Receptors (9 papers) and Antioxidant Activity and Oxidative Stress (9 papers). The work is most often cited by research in Clinical Biochemistry (1.3k citations), Biochemistry (716 citations) and Endocrinology, Diabetes and Metabolism (2.0k citations). Brian J. Van Lenten has collaborated with scholars based in United States, Poland and Netherlands. Frequent co-authors include Alan M. Fogelman, Mohamad Navab, Srinivasa T. Reddy, Susan Hama, Alan C. Wagner, Aldons J. Lusis, G.M. Anantharamaiah, Peter A. Edwards, Judith A. Berliner and Bert N. La Du. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Circulation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact